A settlement calling for Merck & Co. to pay $830 million to investors in multidistrict litigation over the painkiller Vioxx and another $232 million in legal fees received preliminary approval Feb. 11 from a federal judge in Newark.
The settlement would end more than a decade of litigation concerning the company’s statements to shareholders about Vioxx, which was taken off the market over evidence that long-term users were at increased risk of a heart attack or stroke.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
